425: Denali Capital Acquisition Corp. and Semnur Pharmaceuticals Announce $2.5 Billion Merger Agreement

Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, have signed a merger agreement valuing Semnur at $2.5 billion, aiming to create a publicly traded biopharma company.

Summary

• Denali Capital Acquisition Corp. (DECA) and Semnur Pharmaceuticals, a wholly-owned subsidiary of Scilex Holding Company (SCLX), have entered into a merger agreement.
• The deal values Semnur at a pre-transaction equity value of $2.5 billion.
• The merger aims to create a publicly traded biopharma company.
• Scilex is expected to be the majority holder of the combined company, which will be led by an experienced management team.
• The combined entity will focus on advancing Semnur's non-opioid product, SP-102 (SEMDEXA), currently in Phase 3 development for sciatica treatment.
• SP-102 (SEMDEXA) has FDA Fast Track status and projected peak sales of $1.5 billion to $2.0 billion annually.
• The transaction is expected to close by the first quarter of 2025, pending shareholder and regulatory approvals.
• Denali Capital will redomesticate as a Delaware corporation prior to closing.
• Upon closing, the combined company will be renamed Semnur Pharmaceuticals, Inc., with its stock and warrants expected to list on Nasdaq under the symbols SMNR and SMNRW, respectively.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting the potential of SP-102 (SEMDEXA) and the benefits of the merger. The management comments are optimistic, and the projected sales figures are impressive.

Positives

• The merger provides Semnur with access to public markets and capital for further development of SP-102 (SEMDEXA).
• SP-102 (SEMDEXA) has promising market potential, with projected peak sales of $1.5 billion to $2.0 billion annually.
• Scilex's majority ownership provides stability and industry expertise to the combined company.
• The management team of the combined company has a proven track record.
• SP-102 (SEMDEXA) has FDA Fast Track status, potentially accelerating its path to market.

Risks

• The transaction is subject to shareholder and regulatory approvals, and may not close by the expected timeline or at all.
• The combined company's success depends on the successful development and commercialization of SP-102 (SEMDEXA).
• The projected sales of SP-102 (SEMDEXA) are estimates and may not be realized.
• The combined company will face competition in the biopharma industry.
• The potential dividend of Scilex's ownership interest in Semnur is subject to the registration of Semnur's common stock with the SEC and the Scilex board of directors may determine not to proceed with such dividend.

Future Outlook

The combined company will focus on developing and commercializing non-opioid pain therapies, with SP-102 (SEMDEXA) as the lead product candidate. The company will explore potential partnerships and global pharma collaborations.

Management Comments

• Jaisim Shah, Chief Executive Officer and President of Scilex, stated that the business combination will enable the company to advance its growth strategy, including gaining access to public markets and exploring potential partnerships and global pharma collaborations for SP-102 (SEMDEXA).
• Jaisim Shah is proud of the many landmark milestones achieved by the Scilex team since Scilex made its debut on Nasdaq on November 11, 2022, including continuous revenue growth in ZTlido, successful launch of ELYXYB in April 2023 as well as the recent launch of Gloperba in June 2024, and completion of our pivotal Phase 3 study for SP-102 (SEMDEXATM) with a highly successful study results in demonstrating robust efficacy and safety in sciatica patients.

Industry Context

The merger reflects a growing interest in non-opioid pain management solutions, addressing the opioid crisis and seeking safer alternatives for patients with chronic pain conditions.

Comparison to Industry Standards

• Estimates for SP-102 (SEMDEXA) peak sales of $1.5 billion to $2.0 billion annually would place it among the top-selling pain management drugs, comparable to some blockbuster biologics.
• Comparible companies include Pacira BioSciences, Inc. (PCRX) which focuses on non-opioid pain management and has a market cap of around $2.5 billion.
• Another comparible company is BioDelivery Sciences International, Inc. (BDSI) which was acquired by Collegium Pharmaceutical for $604 million.

Stakeholder Impact

• Shareholders of Denali Capital Acquisition Corp. will have the opportunity to vote on the merger.
• Shareholders of Scilex Holding Company may benefit from the increased value of Semnur.
• Patients with sciatica may benefit from the development and commercialization of SP-102 (SEMDEXA).

Next Steps

• The SPAC will file a registration statement on Form S-4 with the SEC, including a proxy statement/prospectus.
• The SPAC will solicit proxies from its shareholders to approve the transaction.
• The parties will seek regulatory approvals.
• The transaction is expected to close by the first quarter of 2025.

Key Dates